Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Rating of “Reduce” from Analysts

Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) have earned an average rating of “Reduce” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $4.77.

TMCI has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. Lake Street Capital cut their price objective on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Treace Medical Concepts in a report on Monday, April 20th.

Insider Buying and Selling at Treace Medical Concepts

In other Treace Medical Concepts news, CEO John T. Treace purchased 61,750 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were purchased at an average price of $2.62 per share, for a total transaction of $161,785.00. Following the completion of the acquisition, the chief executive officer owned 7,158,313 shares of the company’s stock, valued at approximately $18,754,780.06. This represents a 0.87% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have bought 153,763 shares of company stock worth $375,667. Corporate insiders own 23.42% of the company’s stock.

Institutional Trading of Treace Medical Concepts

Several large investors have recently bought and sold shares of TMCI. Graham Capital Management L.P. acquired a new stake in Treace Medical Concepts in the fourth quarter valued at approximately $27,000. Osaic Holdings Inc. grew its position in Treace Medical Concepts by 328.3% in the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock valued at $28,000 after acquiring an additional 3,674 shares in the last quarter. HighTower Advisors LLC acquired a new stake in Treace Medical Concepts in the fourth quarter valued at approximately $33,000. Chicago Partners Investment Group LLC grew its position in Treace Medical Concepts by 34.0% in the first quarter. Chicago Partners Investment Group LLC now owns 26,014 shares of the company’s stock valued at $35,000 after acquiring an additional 6,606 shares in the last quarter. Finally, Balance Wealth LLC acquired a new stake in Treace Medical Concepts in the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 84.08% of the company’s stock.

Treace Medical Concepts Price Performance

NASDAQ:TMCI opened at $2.90 on Thursday. The firm has a market cap of $188.12 million, a price-to-earnings ratio of -2.99 and a beta of 1.10. The company has a current ratio of 3.58, a quick ratio of 2.53 and a debt-to-equity ratio of 0.72. The company’s 50-day moving average is $1.91 and its two-hundred day moving average is $2.25. Treace Medical Concepts has a 12-month low of $1.17 and a 12-month high of $7.78.

Treace Medical Concepts (NASDAQ:TMCI) last released its earnings results on Friday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. The company had revenue of $47.20 million for the quarter, compared to analyst estimates of $45.96 million. Treace Medical Concepts had a negative net margin of 29.44% and a negative return on equity of 67.04%. Research analysts expect that Treace Medical Concepts will post -0.88 EPS for the current year.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.